APP and Alzheimer disease: The OLE aglycone exhibits multiple actions that counteracts the aggregation of the amyloid protein and mitigate its toxicity through various mechanisms; these include the processing of the amyloid precursor protein, the aggregation of the amyloid beta peptide and the tau, impaired autophagy, and neuroinflammation that have therapeutic effects in AD (21, 50–53).